NantBioscience Overview

  • Founded
  • 2013

Founded
  • Status
  • Private

  • Employees
  • 13

Employees
  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $205M

  • Investors
  • 1

NantBioscience General Information

Description

Developer of molecularly targeted drugs designed to treat cancer, infectious diseases, and inflammatory diseases. The company's drugs are targeted at tumor signaling pathways in patients with specific genetic mutations, enabling patients to have access to new therapeutic alternatives.

Contact Information

Formerly Known As
NantBio, Nant Discovery & Developement
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 9920 Jefferson Boulevard
  • Culver City, CA 90232
  • United States
+1 (310) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NantBioscience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 01-Jun-2015 $205M 00000 00000 Completed Startup
To view NantBioscience’s complete valuation and funding history, request access »

NantBioscience Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00.0 000 000 00 000 00.000
To view NantBioscience’s complete cap table history, request access »

NantBioscience Patents

NantBioscience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220033459-A1 Chimeric t cell receptors, nucleic acids, and methods of making and using the same Pending 31-Jul-2020 00000000000
US-20210364496-A1 Interferometry based systems to detect small mass changes of an object in a solution Pending 21-May-2020 00000000000
US-20210093669-A1 Primary t-cell expansion Pending 26-Sep-2019 00000000000
EP-4034641-A1 Primary t-cell expansion Pending 26-Sep-2019 00000000000
EP-4021928-A1 Modified n-810 and methods therefor Pending 29-Aug-2019 C07K16/2827
To view NantBioscience’s complete patent history, request access »

NantBioscience Executive Team (3)

Name Title Board Seat Contact Info
A Banaag Chief Financial Officer
Patrick Soon-Shiong MD Chief Executive Officer, Board Member & Managing Director
You’re viewing 2 of 3 executive team members. Get the full list »

NantBioscience Board Members (1)

Name Representing Role Since
Mark Burnett NantBioscience Board Member 000 0000
To view NantBioscience’s complete board members history, request access »

NantBioscience Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NantBioscience Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Celgene Corporation Minority 000 0000 000000 0
To view NantBioscience’s complete investors history, request access »